The Arctic Group is a leading, independent provider of financial services
Arctic's response to the coronavirus situationRead More
Imøtekom kravet for investeringsselskap i 2018Les mer
For those who have received a request to update their client information.Update now
Arctic Securities is a leading, independent Norwegian investment bank, specializing in corporate finance transactions and advisory services, securities sales and trading as well as equity and credit research.
Arctic Asset Management is an independent Nordic Investment Manager. We specialize in managing Nordic equities, Nordic fixed income and Global Life Science.
The capital raising vehicle for direct investments in the Arctic group. Our primary focus is on real estate, shipping and offshore through investments in equity and debt structures.
Arctic Shipping AS is an independent shipbroker, established in August 2016 as the shipbroking division in the Arctic Group.
Offshore broker covering most types of equipment to the offshore industry as well as project finance and consultancy services
Insurance broker with considerable experience and knowledge. Key focus areas are employees benefits, pension, property and liability insurance.
Authorised external accounting firm offering corporate management, advisory and accounting services.
Dedicated team focused on identification, acquisition and development of real estate with development-/value add potential, on behalf of investors.
Arctic Securities knows that high aspirations and strong motivation are keys to success. In Arctic we nourish our young talent and lay the foundation for Arctic Securities continued success. We want our company to be the place you want to work. We want you to love your job. Because when you love your job, you’ll do great things.
Arctic Securities is acting as Manager in relation to the Subsequent Offering in Nel ASA
On Tuesday this week Arctic Aurora LifeScience portfolio company Albireo Pharma announced positive data from a Phase 3 trial with their drug candidate odevixibat in children and adolescents that suffer from the severely debilitating liver disease Progressive Familial Intrahepatic Cholestasis or PFIC. The Boston, Massachusetts headquartered company with an operational office in Gothenburg, Sweden, will now seek regulatory approvals for the commercial launch of odevixibat in PFIC.
Arctic Securities is acting as financial advisor in relation to the rights issue in ExpreS2ion Biotech Holding AB (publ). ExpreS2ion Biotech Holding AB (publ) is referred to as “Expres2ion” or “the Company”. Shareholders have pre-emptive rights to subscribe for units. Three (1) existing shares held on the record date of October 1, 2020 entitles to one (1) unit consisting of two (2) new shares and one (1) warrant of series TO4 free of charge and one (1) warrant of series TO5 free of charge. Subscription price of SEK 24 per unit, corresponding to SEK 12 per share. The subscription period runs October 5 – October 19, 2020. Three (3) warrants of series TO4 entitles the holder to subscribe for one (1) share in the Company during the period from April 12, 2021 to April 26, 2021. Strike price for warrants will correspond to 70 percent of the VWAP of the Company's share on Nasdaq First North Growth Market during the period from March 29, 2021 to April 9, 2021, but at least SEK 6 and a maximum of SEK 22 per share. Three (3) warrants of series TO5 entitles the holder to subscribe for one (1) share in the Company during the period from September 6, 2021 to September 20, 2021. Strike price for warrants will correspond to 70 percent of the VWAP of the Company's share on Nasdaq First North Growth Market during the period from August 23, 2021 to September 3, 2021, but at least SEK 6 and a maximum of SEK 25 per share. The rights issue is secured up to 100 percent through subscription- and guarantee undertakings. A Swedish prospectus and subscription note will be available before the subscription period on Expres2ion’s website, www.expres2ionbio.com and Arctic Securities website.